home / stock / embi / embi news

EMBI News and Press, Emerald Bioscience Inc From 10/15/19

Stock Information
Company Name: Emerald Bioscience Inc
Stock Symbol: EMBI
Market: OTC
Menu
EMBI EMBI Quote EMBI Short EMBI News EMBI Articles EMBI Message Board
Get EMBI Alerts

News, Short Squeeze, Breakout and More Instantly...
EMBI - Emerald Bioscience's NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model

LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced data demons...
EMBI - Glauconix Presents Data Validating Impact of Emerald Bioscience's Prodrug on the Ocular Endocannabinoid System in Glaucoma

Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA - ( NewMediaWire ) - October 15, 2019 - Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medic...

EMBI - Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience's Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting

Long Beach, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Glauconix Bi...

EMBI - Emerald Bioscience to Participate in Investment and Scientific Conferences in September

Long Beach, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Brian Murphy...
EMBI - Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations

Long Beach, CA, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Emerald Bioscience, Inc.  (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, announced today the appointments of Dennis D. Kim, MD, MBA, as Chief&...

EMBI - Emerald Bioscience Starts Australian Operation Ahead of Planned Glaucoma Study

Pre-clinical studies of cannabidiol analog to commence Long Beach, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially th...

EMBI - Emerald Bioscience to Participate in 29th Annual International Cannabinoid Research Symposium (ICRS)

Long Beach, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that two posters ...
EMBI - Emerald Bioscience's NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol

Journal of Ocular Pharmacology and Therapeutics Peer-Reviewed Journal Publishes NB2222 Ocular Bioavailability Data LONG BEACH, CA, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabi...

EMBI - Emerald Bioscience to Present at the 9th Annual LD Micro Invitational

LONG BEACH, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that Dr. Brian Murphy, Chief Executive Off...

EMBI - Emerald Bioscience Secures "All Fields" Licenses for Cannabinoid Derivatives Developed by University of Mississippi

Licenses Permit Emerald to Develop THC-Prodrug and CBD-Analog for Any Therapeutic Indication by Any Route of Administration for Human and Veterinary Use LONG BEACH, CA, May 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutic...
Previous 10 Next 10